ZEVRA THERAPEUTICS INC

Zevra Therapeutics Inc (ZVRA), the Palo Alto–based rare-disease and lysosomal-storage-disorder developer whose lead program targets the mucopolysaccharidosis and Gaucher-disease populations, now has 143 institutional holders across approximately $383 million in aggregate value — a small but growing register that took two structurally important steps forward in Q1 2026. First, Vanguard crossed the dual-entry threshold: Vanguard Capital Management opened a $23 million position and Vanguard Portfolio Management added $4.3 million simultaneously, a fingerprint of the float-and-liquidity inclusion signal that marks a name's passage into at least one broad-market index sleeve. Second, FMR (Fidelity) made the largest single-addition in the file by far, growing its holding from $24 million to $30 million on an 82% share increase, while Nantahala Capital added $7.6 million in new shares, Point72 Asset Management opened a fresh $10.8 million position, and Kingdon Capital, Qube Research & Technologies, Goldman Sachs, and Morgan Stanley all built or initiated positions across the quarter. The offset was quieter: Millennium, Tudor Investment, Jane Street, Caption Management, and Woodline Partners trimmed slightly, and AIGH Capital opened a smaller new position. The net result is a register that expanded modestly in dollar terms but grew substantially in the diversity of its holder base — moving from a concentrated, specialist biotech roster toward one that includes the kind of systematic, quality-focused, and passive institutions that validate a small-cap biotech's entry into broader market indices.